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Objective: The aim of this study was to analyse the effectiveness of single dose of 20 mg/kg intravenous
tranexamic acid (TXA), in reducing the blood loss in patients undergoing total knee arthroplasty (TKA).
Material and method: 70 patients (65.5 ± 8.1 years old) that have undergone TKA were divided in two
groups. The 20 mg/kg IV TXA was given before the skin incision to one group (study group). On the
control group, TKA was performed without TXA. The demographic data, body mass index, amount of
bleeding and erythrocyte infusion during the operation, hemoglobin and hematocrit values (preopera-
tive and 48th hour), the amount of drainage after the operation were compared between the groups.
Results: The total amount of bleeding in the study group was 634.03 ± 182.88 ml and
1166.42 ± 295.92 ml in the control group (p < 0.001). Perioperative bleeding was 252.01 ± 144.13 ml in
the study group and 431.33 ± 209.10 ml in the control group (p ¼ 0.018). The drainage after the operation
was 311.11 ± 141.64 ml at the 24th hour in the study group, 640.74 ± 279.43 ml at the 24th hour in the
control group (p < 0.001). The drainage after 24th hour was 97.96 ± 115.86 ml in the study group and
112.96 ± 64.43 ml in the control group (p ¼ 0.584).
Conclusion: A high, single dose of TXA intravenously given to the patient prior to the TKA signiﬁcantly
reduces the bleeding during the operation and within the postoperative 24 h. There is no signiﬁcant
change in the bleeding amount after the 24th hour following the operation.
© 2016 Turkish Association of Orthopaedics and Traumatology. Publishing services by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Introduction
Total knee arthroplasty (TKA) is a method that has proven to be
effective in treatment of severe knee arthrosis. Although it is a
successful treatment, arthroplasty may cause certain adverse
events. For example, 500e1500 cc of blood loss has been reported
following the procedure.1e4 The blood loss may cause prolonged
physical treatment, increased infection rates, prolonged length of
hospital stay, and side effects caused by the need for transfusion.5e7l).
ciation of Orthopaedics and
s and Traumatology. Publishing seThe literature describes a number of modalities which have
been reported to produce a signiﬁcant reduction in the volume of
blood loss.1e6,8,9 Tranexamic acid (TXA), intravenous (IV) or topical,
is one such modality,7,8,10e14 with both modes of administration
having been shown effective.3 TXA produces its hemostatic effect
through plasminogen activation and by creating an inhibitory effect
on active plasmin. The effect of TXA on blood loss lasts for 7e8 h in
serum and for a longer period in tissue.8,10,14,15
In the present study, the effects of 20mg/kg IV TXA on blood loss
during and after unilateral TKA when administered preoperatively
were reviewed prospectively.rvices by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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Our study was performed with the approval of the institutional
ethics committee. Seventy patients diagnosed with ASA (American
Society of Anesthesiologists) grade 1e3 gonarthrosis who were
scheduled for knee arthroplasty were included in this prospective
observational review. Exclusion criteria for the study were pro-
longed use of anticoagulant medication, chronic renal impairment,
previous history of deep venous thrombosis (DVT) or pulmonary
embolism (PE), having undergone revision surgery and simulta-
neous bilateral knee arthroplasty, having thrombocyte level below
150,000 and INR level above 1.4, and having rheumatic or hema-
tological diseases.
Thepatients included in the studyweredivided into2groups. The
study group received 20 mg/kg IV TXA 20 min before the skin inci-
sion,withuseof a tourniquetonlyduring thecementationphase. The
control group received knee arthroplasty without TXA. All patients
received neuroaxial anesthesia (spinal or combined spinal epidural).
Knee arthroplastywas performedwith standardmedial parapatellar
incision, with use of an intramedullary guide for the femur and
extramedullary guide for the tibia section. The same type of knee
implant protecting the posterior cruciate ligaments was used on all
patients. Prophylactic treatment with 2 g cefazolin was initiated
30 min prior to the operation and continued for 24 h as 1 g admin-
istered 4 times/day. The patients were mobilized with partial
weights and crutches within the ﬁrst 24 h after the operation. The
drainage in patients was recorded at the 24th and 48th hour. One
doseof0.4ml (4000 IU)enoxaparin (Clexane, 4000anti-Xa IU/0.4ml,
Sanoﬁ-Aventis, Gentilly, France) was given 12 h prior to the surgery
subcutaneously as the standard application. At the time of discharge,
the patients were given 100 mg/day acetylsalicylic acid. The
threshold for allogeneic blood replacementwas considered as 7 g/dl,
with the exception of patients with serious conditions of comor-
bidities or cardiac diseases (such as coronary artery disease, cere-
brovascular events, or cardiac insufﬁciency)when the thresholdwas
changed to10g/dl. Patients received1unitof allogeneic erythrocytes
when hemoglobin values dropped below these thresholds. The vol-
umeof blood lost intraoperativelywas calculated from the volumeof
blood in the aspirator and irrigation ﬂuid, plus the volume of blood
on the gauze pad (calculated by weighing the gauze pads).
Patients' demographic data, body mass indexes, volume of
intraoperative blood loss and erythrocyte infusion, hemoglobin and
hematocrit values preoperatively and 48 h postoperatively, and the
volume of blood drainage during the ﬁrst 24 and 48 (total value
from ﬁrst 24-h period, plus additional volume measured in second
24-h period) h after the operation were reviewed.
Student's t-test was used for evaluating quantitative data with
normal distribution and ManneWhitney U test for data not having
normal distribution. Chi-square test was used to evaluate qualita-
tive data. Statistical signiﬁcance was established at p < 0.05. SPSS
software (version 20.0, SPSS Inc., Chicago, IL, USA) was used for
statistical analysis.Table 1
Postoperative blood loss data.
TXA group
(n ¼ 35)
Drains 0e24 h (ml) 311.11 ± 141.64
Drains 24e48 h (ml) 97.96 ± 115.86
Total volume of drains (ml) 392.03 ± 160.65
Total volume of blood loss (ml) 634.03 ± 182.88
*p < 0.05 considered signiﬁcant.
a Student's t-test.Results
Study patients were divided into 2 groups of 35 patients (mean
age: 64.5± 8.1 years). Therewere no signiﬁcant differences in terms
of patient demographic data. Body mass index was 32.8 ± 0.6 in the
study group and 35 ± 5.9 in the control group (p ¼ 0.165).
The results of the study showed that the total volume of blood
loss was signiﬁcantly reduced in the study group that received TXA
(634.03 ± 182.88 ml) compared to the control group
(1166.42 ± 295.92 ml) (p < 0.001).
The volume of blood loss during the operation was also signif-
icantly reduced in the study group (252.01 ± 144.13 ml) compared
to the control group (431.33 ± 209.10 ml) (p ¼ 0.018). Similarly, the
allogeneic transfusion level in the study group was signiﬁcantly
lower than in the control group (Table 2).
Hemoglobin values both pre- and postoperatively were not
signiﬁcantly different between the study and control groups.
The total volume of blood loss postoperatively was signiﬁcantly
lower in the study group compared to the control group at both the
24th hour and 48th hour time points: the study group was
311.11 ± 141.64 ml at the 24th hour and 392.03 ± 160.42 ml at the
48th hour, while the control group 640.74 ± 279.43 ml at the 24th
hour and 746.43 ± 271.80 ml at the 48th hour (p < 0.001 for both
comparisons). Drainage after the 24th hour was 97.96 ± 115.86 ml
in the study group that received TAX and 112.96 ± 64.43 ml in the
control group, with no signiﬁcant difference between the groups
(p ¼ 0.584) (Table 1).
One patient in the study group of TXA treatment developed an
adverse event of PE in the third week postoperatively, which was
medically treated (p ¼ 0.314).Discussion
The beneﬁt of TXA use as an antiﬁbrinolytic agent to reduce
blood loss after knee arthroplasty was ﬁrst described by Hippala
et al.12 TXA has been generally used in dental surgery, cardiac
surgery, and the treatment of hemophilia disease as an anti-
hemorrhagic agent but is now beginning to be used in arthro-
plasty surgery.
A number of publications indicate signiﬁcant reduction in the
volume of blood loss.7,8,10e12,14 The literature states the blood loss
volumes as ranging between 360 ml and 800 ml. In the present
study, the average volume of blood loss in the study group was
634.03 ± 182.88ml, which is in accordancewith the volumes stated
in the literature and was signiﬁcantly lower than the blood loss in
the control group, which did not receive TXA (1166.42 ± 295.92 ml)
(p < 0.001). The volume of blood loss in the study group was close
to the upper limit stated in the literature, despite the TXA treat-
ment, because tourniquet was not used during the operation;
additionally, perioperative blood loss was included in the total
volume of blood loss. The volume of postoperative blood loss was
392.03 ± 160.65 ml.Control group
(n ¼ 35)
ap-value
640.74 ± 279.435 <0.001*
112.96 ± 64.43 0.584
746.43 ± 271.80 <0.001*
1166.42 ± 295.92 <0.001*
Table 2








252.01 ± 144.13 431.33 ± 209.10 a0.018*
Perioperative
transfusion (unit)
0.74 ± 0.44 1.02 ± 0.38 a0.006*
*p < 0.05 considered signiﬁcant.
a Student's t-test.
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methods, or volume of usage of TXA.14,16e19 Multiple doses or
topical use combined with IV administration is claimed to be more
successful than single-dose usage.17,18 Hourlier et al showed in their
study that the single-dose TXA method is as effective as the mul-
tiple dose method.16 They stated that the previous studies failed to
show the efﬁcacy of single-dose treatment because they usually
used low doses and that the efﬁcient dose should be 30 mg/kg.16
TXA begins to take effect within 15 min of administration and re-
mains effective for 7e8 h in serum and up to 17 h in tissue. The fact
that the majority of blood loss occurs within the ﬁrst 5 h after the
operation9,20 indicates that preoperative IV TXA treatment has a
sufﬁciently fast effect on blood loss. In our study, the volume of
blood loss experienced during the ﬁrst 24 h postoperatively was
311.11 ± 141.64 ml in the study group and 640.74 ± 279.435 ml in
the control group (p < 0.001). However, there were no signiﬁcant
differences between the volumes of blood loss in the 2 groups after
the 24th hour (p¼ 0.58). Treatment with a high dose of TXA 20min
before the skin incision creates a statistically signiﬁcant reduction
in blood loss volume both during and after the operation compared
to standard treatment.
The volume of blood loss during the operation was signiﬁcantly
reducedwith TXA treatment prior to the operation compared to the
non-TXA group (p ¼ 0.018). The literature conﬁrms the statistically
signiﬁcant reduction in blood loss in a meta-analysis.19 These dif-
ferences can be explained with the dose used and timing of the
treatment.
The literature indicates that bolus blood loss occurs despite TXA
treatment in patients subject to tourniquet use.18 The authors
recommend opening of the drain 1 h after the operation to avoid
bolus blood loss. Our use of tourniquet only during cementation
helped us avoid bolus blood loss and permitted hemostasis in our
study. Furthermore, since TXA was applied immediately before the
operation, it was effective, and bolus blood loss did not occur in our
study.
The literature generally states that use of TXA to control blood
loss does not create the risk of DVT or PE and that TXA treatment is
safe.16,21 Zhang et al, however, found in their meta-analysis study
that 5 of their patients had PE, 2 of whomwere among the patients
who had received TXA.14 In our study, PE was diagnosed in 1 of 30
patients, who was treated with anticoagulant therapy. This single
occurrence was not signiﬁcant (p ¼ 0.356). One restriction of the
present study was that there was no standard protocol for moni-
toring of patients with venography in order to diagnose possible
DVT.
The preoperative use of single and high dose of TXA on patients
undergoing TKA signiﬁcantly reduces the volume of blood lossduring the operation and in the ﬁrst 24 h postoperatively. There
was no signiﬁcant difference in blood loss volume after the 24th
hour, a period in which little blood loss is typically observed.Conﬂict of interest
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